# Cigna Group vs Takeda Pharmaceutical: stocks compared

URL: https://funkfolio.com/compare/ci-vs-tak

> Cigna Group ($77.5B, P/E 13.0) and Takeda Pharmaceutical ($69.1B, P/E 309) compared: size, valuation, margins, debt, cash and price change.

---

## Cigna Group vs Takeda Pharmaceutical

Cigna Group (CI), health care, and Takeda Pharmaceutical (TAK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Cigna Group is worth $77.5B on the stock market and Takeda Pharmaceutical $69.1B: Cigna Group is valued at 12% more. Cigna Group trades at 13.0 times earnings and Takeda Pharmaceutical at 309; operating margins in their latest fiscal years were 3.35% and 0.14%. Over the past year Cigna Group's share price has moved +10.1% and Takeda Pharmaceutical's +53.4%.

### Key facts

- **Cigna Group market value:** $77.5B
- **Takeda Pharmaceutical market value:** $69.1B
- **Cigna Group P/E:** 13.0
- **Takeda Pharmaceutical P/E:** 309
- **Cigna Group revenue:** $274.9B FY to 2025-12-31
- **Takeda Pharmaceutical revenue:** $28.2B FY to 2026-03-31
- **Superinvestors holding both:** 2

Market values as of 18 Nov 2026, 01:10 UTC.

Cigna Group vs Takeda Pharmaceutical: every measure side by side

| Measure | Cigna Group | Takeda Pharmaceutical |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Japan |
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size |  |  |
| Market cap | $77.5B higher | $69.1B lower |
| Revenue | $274.9B higher | $28.2B lower |
| Earnings | $6B higher | -$954.4M lower |
| Employees | 65,669 higher | 47,029 lower |
| Total assets | $157.9B higher | $97.1B lower |
| Valuation |  |  |
| P/E | 13.0 lower | 309 higher |
| P/S | 0.3 lower | 2.5 higher |
| P/B | 1.8 | — |
| Dividend yield | 2.06% | — |
| Profitability |  |  |
| Operating margin | 3.35% higher | 0.14% lower |
| Balance sheet |  |  |
| Net assets | $41.7B lower | $46.5B higher |
| Total liabilities | $116B higher | $50.6B lower |
| Total debt | $31.5B higher | $30.6B lower |
| Cash on hand | $7.7B higher | $3.7B lower |
| Price change |  |  |
| Today | -2.03% lower | +0.23% higher |
| 1 year | +10.1% lower | +53.4% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Cigna Group 110.6, Takeda Pharmaceutical 152.7.

- Cigna Group (CI)
- Takeda Pharmaceutical (TAK)

Cigna Group and Takeda Pharmaceutical share prices over one year, rebased to 100: Cigna Group ends at 110.6, Takeda Pharmaceutical at 152.7.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | CI | TAK |
| --- | --- | --- |
| Nov 28, 2025 | 102.2 | 102.0 |
| Dec 31, 2025 | 101.4 | 110.3 |
| Jan 30, 2026 | 101.0 | 121.9 |
| Feb 27, 2026 | 106.8 | 132.6 |
| Mar 31, 2026 | 98.3 | 131.0 |
| Apr 30, 2026 | 107.1 | 118.0 |
| May 29, 2026 | 102.2 | 112.9 |
| Jun 30, 2026 | 101.6 | 113.4 |
| Jul 31, 2026 | 102.8 | 120.9 |
| Aug 31, 2026 | 101.8 | 127.2 |
| Sep 30, 2026 | 100.2 | 128.6 |
| Oct 30, 2026 | 109.9 | 147.9 |
| Nov 16, 2026 | 110.6 | 152.7 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (2)

- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 1.7% / 0.5%
- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) 0.4% / &lt;0.1%

#### Cigna Group only (13)

- [Anthony Bozza](https://funkfolio.com/gurus/anthony-bozza) 6.0%
- [Andrew Wellington](https://funkfolio.com/gurus/andrew-wellington) 2.8%
- [Lew Sanders](https://funkfolio.com/gurus/lew-sanders) 2.7%
- [Christopher Davis](https://funkfolio.com/gurus/christopher-davis) 2.7%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 2.3%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 1.8%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.5%
- [Louis Bacon](https://funkfolio.com/gurus/louis-bacon) 0.8%
- [David Einhorn](https://funkfolio.com/gurus/david-einhorn) 0.6%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 0.3%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.3%
- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.2%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1%

#### Takeda Pharmaceutical only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Cigna Group / Takeda Pharmaceutical). [Who owns CI](https://funkfolio.com/stock/CI/superinvestors) · [Who owns TAK](https://funkfolio.com/stock/TAK/superinvestors)

### More on Cigna Group

- [Cigna Group (CI) stock page](https://funkfolio.com/stock/CI)
- [Cigna Group market cap](https://funkfolio.com/stock/CI/market-cap)
- [Cigna Group revenue](https://funkfolio.com/stock/CI/revenue)
- [Cigna Group P/E ratio](https://funkfolio.com/stock/CI/pe-ratio)
- [Cigna Group operating margin](https://funkfolio.com/stock/CI/operating-margin)
- [Cigna Group total debt](https://funkfolio.com/stock/CI/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Takeda Pharmaceutical

- [Takeda Pharmaceutical (TAK) stock page](https://funkfolio.com/stock/TAK)
- [Takeda Pharmaceutical market cap](https://funkfolio.com/stock/TAK/market-cap)
- [Takeda Pharmaceutical revenue](https://funkfolio.com/stock/TAK/revenue)
- [Takeda Pharmaceutical P/E ratio](https://funkfolio.com/stock/TAK/pe-ratio)
- [Takeda Pharmaceutical operating margin](https://funkfolio.com/stock/TAK/operating-margin)
- [Takeda Pharmaceutical total debt](https://funkfolio.com/stock/TAK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Cigna Group against its closest peers

- [Cigna Group vs Elevance Health](https://funkfolio.com/compare/ci-vs-elv)
- [Cigna Group vs Cencora](https://funkfolio.com/compare/ci-vs-cor)
- [Cigna Group vs Regeneron Pharmaceuticals](https://funkfolio.com/compare/ci-vs-regn)

#### Takeda Pharmaceutical against its closest peers

- [Takeda Pharmaceutical vs Cencora](https://funkfolio.com/compare/cor-vs-tak)
- [Takeda Pharmaceutical vs Boston Scientific](https://funkfolio.com/compare/bsx-vs-tak)
- [Takeda Pharmaceutical vs Cardinal Health](https://funkfolio.com/compare/cah-vs-tak)
- [Takeda Pharmaceutical vs argenx](https://funkfolio.com/compare/argx-vs-tak)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Cigna Group or Takeda Pharmaceutical?**

By market value, Cigna Group is the larger: $77.5B against $69.1B for Takeda Pharmaceutical. By revenue in its latest fiscal year, Cigna Group is the larger: $274.9B against $28.2B for Takeda Pharmaceutical.

**Which has the higher P/E ratio?**

Takeda Pharmaceutical: 309, against 13.0 for Cigna Group. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Cigna Group: 3.35%, against 0.14% for Takeda Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

Cigna Group: $31.5B, against $30.6B for Takeda Pharmaceutical. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Cigna Group and Takeda Pharmaceutical?**

In their latest 13F filings, Charles Brandes (founder) and Richard Pzena hold both.

### Cite this page

Funkfolio, “Cigna Group vs Takeda Pharmaceutical”, data as of 18 November 2026. https://funkfolio.com/compare/ci-vs-tak

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
